1G. Seipelt,W.-K. Hofmann,H. Martin,B. Wassmann,A. Boehme,O. G. Ottmann,D. Hoelzer. Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin[J] 1998,Annals of Hematology(3-4):145～151
2V. Nüssler,F. Gieseler,H. Zwierzina,E. Gullis,R. Pelka-Fleischer,H. Diem,W. Abenhardt,R. Schmitt,I. Langenmayer,A. Wohlrab,H.-J. Kolb,W. Wilmanns. Idarubicin monotherapy in multiply pretreated leukemia patients: response in relation to P-glycoprotein expression[J] 1997,Annals of Hematology(2):57～64
3J. P. Laporte,N. C. Gorin,M. P. Lemonnier,F. Isnard,A. Najman. A new combination of two intercalating agents (mitoxantrone + daunomycin) in adult refractory acute leukemia: the DON protocol[J] 1988,Cancer Chemotherapy and Pharmacology(4):344～346
